Pharma companies are a necessity for a country and its mankind. Without them, we would have never had the kind of treatments and medications that are available to us today. The pharmaceutical industry has various companies that provide solutions to various problems. There are companies that focus on one specific problem and create multiple products that will help with those ailments. Some companies are engaged in developing medications and treatments while others are engaged in developing devices that will help in better functioning of the human body. Each one of these companies contributes to having better medical facilities that enhance human life.
Investing in pharma companies gives them much-needed capital for running operations. The money is used for research and development among other core activities of the company. Investing in such companies gives them the much-needed boost to carry out operations that can lead to a positive impact on human life. These companies may not be the most profitable, especially the ones that are just starting out, but with a successful clinical trial, it shows potential for great returns in the future. Biopharmaceuticals is a branch of this industry whose returns depend upon the success of their products, as the products are tailor-made to target the root cause of a health problem.
One such company engaged in the pharmaceutical industry is Albireo Pharma. The company’s focus is on developing and commercializing novel bile acid regulators that will help in treating orphan pediatric liver diseases and gastrointestinal disorders. The company’s product candidate is A4250 which is an orally administered ileal sodium-dependent bile acid transporter (IBAT) inhibitor which will be useful in treating progressive familial intrahepatic cholestasis and other cholestatic liver diseases. The company is developing another product called Elobixibat which is an orally administered IBAT inhibitor for treating chronic constipation, non-alcoholic steatohepatitis, and other functional diseases.
Albireo Pharma is listed on Nasdaq under the ticker ‘ALBO’. The company is headquartered in Boston, Massachusetts. It has a market cap worth $380.77 million and is currently trading for $25.40 per share. NASDAQ: ALBO at https://www.webull.com/quote/nasdaq-albo has a consensus ‘buy’ rating from various analysts. According to analysts, the stock has a potential upside of 104.5%, with a price target of $51.67. Before the covid-19 pandemic, the stock traded at $17.63 in March 2020. It has now risen to $25.40, showing an increase of 44.1% NASDAQ: ALBO reported EPS of -$1.38, which is $0.27 less than the analysts’ estimates of -$1.65. Key competitors are Corcept Therapeutics, Zogenix, Portola Pharmaceuticals, Myovant Sciences, MacroGenics, ALX Oncology, etc. If you do not know where to buy stocks online, you can download a stock trading app.
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.August 22, 2020